Home › Chronic Lymphocytic Leukemia › North Carolina › Charlotte
Pag-aaral pangklinika para sa Chronic Lymphocytic Leukemia sa Charlotte, NC
9 pag-aaral para sa Chronic Lymphocytic Leukemia ang naghahanap ng mga kalahok sa mga site sa loob at paligid ng Charlotte (sa loob ng humigit-kumulang 30 milya). Buksan ang pag-aaral upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
Nagre-recruitPhase 1/2
- Research Site, Charlotte
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
Nagre-recruitPhase 3
- Atrium Health Levine Cancer Institute (Lci), Charlotte
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Nagre-recruitPhase 3
- Levine Cancer Center, Charlotte
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Nagre-recruitPhase 3
- Atrium Health Levine Cancer Institute (Lci), Charlotte
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
Nagre-recruitPhase 3
- Carolina Oncology Specialists, PA ( Site 0054), Charlotte
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
Nagre-recruitPhase 1/2
- Research Site, Charlotte
- Research Site, Charlotte
Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab
Nagre-recruitPhase 2
- Research Site, Charlotte
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Nagre-recruitPhase 3
- Atrium Health /ID# 267219, Charlotte
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
Nagre-recruitPhase 2
- Novant Health Presbyterian Medical Center /ID# 230201, Charlotte
Pag-aaral para sa Chronic Lymphocytic Leukemia sa ibang lungsod
- Boston, MA31 pag-aaral
- Columbus, OH28 pag-aaral
- Durham, NC27 pag-aaral
- Washington, DC22 pag-aaral
- Seattle, WA20 pag-aaral
- New York City, NY18 pag-aaral
- Rochester, MN18 pag-aaral
- Houston, TX17 pag-aaral
- Baldwin Park, CA16 pag-aaral
- Milwaukee, WI15 pag-aaral
- Chicago, IL14 pag-aaral
- Cincinnati, OH14 pag-aaral
Iba pang pag-aaral sa Charlotte
- Kanser (lahat ng uri)27 pag-aaral
- Kanser sa Suso22 pag-aaral
- Multiple Myeloma21 pag-aaral
- Non-Small Cell Lung Cancer19 pag-aaral
- Acute Myeloid Leukemia16 pag-aaral
- Obesity16 pag-aaral
- Overweight15 pag-aaral
- Colorectal Cancer13 pag-aaral
- Kanser sa Ovary12 pag-aaral
- Pagkabigo ng Puso11 pag-aaral
- Metastatic Cancer11 pag-aaral
- Squamous Cell Carcinoma ng Ulo at Leeg10 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.